Humoral Response and Safety after a Fourth Dose of the SARS-CoV-2 BNT162b2 Vaccine in Cancer Patients Undergoing Active Treatment-Results of a Prospective Observational Study.

Humoral Response and Safety after a Fourth Dose of the SARS-CoV-2 BNT162b2 Vaccine in Cancer Patients Undergoing Active Treatment-Results of a Prospective Observational Study.

Publication date: Jan 12, 2024

Only a few studies have been carried out on the efficacy and safety of a fourth dose of the COVID-19 vaccine in patients with cancer. In this prospective observational study, we aimed to assess the serological response and safety of the fourth booster shot of the BNT162b2 vaccine in 79 cancer patients, vaccinated between 1 March and 25 August 2022, under systemic anticancer therapy. The primary endpoint was to assess the increase in the anti-SARS-CoV-2 antibodies; secondary endpoints were the vaccine safety and side effects. Consequently, 40 patients (50. 63%) revealed the maximum detection values in their IgG titers before the fourth dose of the vaccine, while 39 patients (49. 37%) did not. Primary endpoint: Of 39 patients, 36 (92. 31%) showed a significant increase in the anti-SARS-CoV-2 IgG titers, and 32 of them (82. 05%) reached the maximum titration values. Secondary endpoints: The most common adverse events were mild in severity and included injection site pain, erythema and tiredness. The majority of the adverse reactions reported were grade 1 and no grade 3 and 4 reactions were detected. Our data provide evidence that a fourth dose of the BNT162b2 anti-SARS-CoV-2 vaccine is effective and safe in patients with solid tumors in active anticancer treatment.

Open Access PDF

Concepts Keywords
Basel booster
Cancer cancer
Humoral COVID-19 vaccines
Vaccinated efficacy
safety

Semantics

Type Source Name
disease VO dose
disease VO vaccine
disease MESH Cancer
disease VO COVID-19 vaccine
disease VO vaccinated
disease VO injection
disease IDO site
disease MESH erythema
disease VO effective
disease MESH COVID 19
disease MESH complications
disease IDO immunosuppression
disease VO efficient
drug DRUGBANK Coenzyme M
disease VO vaccination
disease MESH seroconversion
pathway REACTOME Immune System
disease VO vaccine dose
disease VO Hormone
disease IDO history
drug DRUGBANK Trastuzumab
drug DRUGBANK Bevacizumab
drug DRUGBANK L-Tyrosine
disease IDO blood
disease IDO assay
disease IDO process
disease VO population
disease VO adverse event
disease VO nose
disease VO effectiveness
disease VO titer
disease IDO symptom
disease MESH infections
disease IDO country
drug DRUGBANK Etoperidone
disease MESH breast cancer
pathway KEGG Breast cancer
disease MESH cervical cancer
disease MESH colorectal cancer
pathway KEGG Colorectal cancer
disease MESH adenomas
disease VO time
disease IDO intervention
disease MESH death
disease IDO infection
disease MESH uncertainty
disease VO vaccine efficacy
disease MESH rheumatic disease
disease IDO immunodeficiency
disease MESH blood cancers
disease VO protocol
disease MESH immunocompromised patients
disease MESH infectious diseases
disease VO Iss
drug DRUGBANK Safrazine
disease VO coronavirus vaccine
disease MESH chronic lymphocytic leukemia

Original Article

(Visited 1 times, 1 visits today)